Pancreatic ductal adenocarcinoma (PDAC) features a prominent stromal microenvironment
with remarkable cellular and spatial heterogeneity that meaningfully impacts disease …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …

Intratumoral heterogeneity is a critical frontier in understanding how the tumor
microenvironment (TME) propels malignant progression. Here, we deconvolute the human …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …

Pancreatic ductal adenocarcinoma (PDAC), already among the deadliest epithelial
malignancies, is rising in both incidence and contribution to overall cancer deaths. Decades …

Neoadjuvant chemotherapy can improve the survival of individuals with borderline and
unresectable pancreatic ductal adenocarcinoma; however, heterogeneous responses to …

Pancreatic cancer is a genetic disease, and the recurrent genetic alterations characteristic of
pancreatic cancer indicate the cellular processes that are targeted for malignant …

KRAS inhibitors demonstrate clinical efficacy in pancreatic ductal adenocarcinoma (PDAC);
however, resistance is common. Among patients with KRAS G12C-mutant PDAC treated …

Pancreatic ductal adenocarcinoma (PDAC) has a rising incidence and is one of the most
lethal human malignancies. Much is known regarding the biology and pathophysiology of …

The tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDAC) is a
complex ecosystem that drives tumor progression; however, in-depth single cell …